Qlaris Bio, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies for glaucoma, today ...
DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical‐stage biotechnology company dedicated to developing first‐in‐class therapies for glaucoma, today announced that new data from studies of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with primary open-angle glaucoma or ocular ...
QLS-111 added to latanoprost drove up to 3.6 mmHg greater reduction in IOP as compared to latanoprost alone DEDHAM, Mass., February 05, 2025--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage ...
Life Time Fitness recently announced its purchase of QLS Family Fitness. As of June 1, Life Time Fitness acquired QLS but the day-to-day operations will remain the same as well as the staff. Employees ...
DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing ...
Qlaris Bio has reported positive topline outcomes from two randomised Phase II US trials, Osprey and Apteryx, of QLS 111 in individuals with primary open-angle glaucoma (POAG) and ocular hypertension ...
Strategies will focus on public and private companies developing potentially life-changing medical treatments Partnership combines the insights and scale of BlackRock’s active investment platform with ...
QLS-111’s novel intraocular pressure-lowering mechanism targeting EVP to be highlighted in an oral presentation and two poster presentations DEDHAM, Mass., June 23, 2025--(BUSINESS WIRE)--Qlaris Bio, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results